Biotechnology News

Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 mars 2026 (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Place de...

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of March 31, 2026 (Article 223-16 of the General Regulations of the Autorité des Marchés...

HUNTSVILLE, April 02, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ...

NEEDHAM, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal...

LA JOLLA, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today...

Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions

MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million YAVNE, Israel, April 2, 2026 — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic...

CAMBRIDGE, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, has been awarded a...

Faits financiers marquants de 2025 : Trésorerie et équivalents de trésorerie s’élevant à 101.1 millions d’euros au 31 décembre 2025 Chiffre d’affaires s’élevant à 65.4 millions d’euros au 31 décembre...

2025 financial highlights: Cash and cash equivalents totaled €101.1 million as of December 31, 2025Revenues amounting to €65.4 million for the period ended December 31, 2025, including €43.6 million...